Form 4: VYNE CEO's Tax Withholding on Stock Vesting

VYNE Therapeutics CEO David Domzalski reported the withholding of 12,676 common shares to cover tax obligations related to restricted stock unit vesting.

Summary

• David Domzalski, President and CEO, and a Director of VYNE Therapeutics Inc., reported a transaction on September 30, 2025.
• The transaction involved the disposition of 12,676 shares of common stock.
• These shares were withheld by VYNE Therapeutics Inc. to satisfy tax withholding requirements associated with the vesting of restricted stock units.
• The price per share for the withheld stock was $0.335.
• Following this transaction, David Domzalski directly beneficially owns 428,892 shares of VYNE Therapeutics Inc. common stock.

Sentiment

Score: 5

Explanation: This is a routine, non-discretionary transaction for tax purposes related to RSU vesting, which is a standard part of executive compensation. It does not indicate a positive or negative sentiment towards the company's prospects.

Future Outlook

NA

Industry Context

NA

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary tax withholding event related to the vesting of restricted stock units for the CEO. It does not reflect a discretionary sale or purchase of shares and therefore provides no new fundamental information to alter an investment recommendation. Investors should maintain their current position based on broader company fundamentals.

Keywords

VYNE Therapeutics, VYNE, David Domzalski, Form 4, insider transaction, stock vesting, tax withholding, common stock, CEO, director